Quintrio
Home

PHARMACEUTICAL PREPARATIONS

ADARx Pharmaceuticals, Inc. Common Stock

ADRX

Adarx Pharmaceuticals Inc is a late-clinical stage biotechnology company focused on developing next-generation siRNA therapeutics designed to treat a broad spectrum of diseases. Its pipeline includes three clinical-stage programs and two advanced preclinical programs. The three hepatic-targeted programs are agazisiran, onvuzosiran, and ADX-626, while the two extrahepatic-targeted programs are ADX-077 and ADX-199.

Last trade $13.99
Day change -$0.015 (-0.11%)
Day range $13.02 – $14.87
Volume 490,256
Market cap $1.55B

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

No ratio data was found for ADRX.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for ADRX, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026
Revenue$2.22M
Cost of revenue$0
Gross profit$2.22M
Selling, general and administrative$7.68M
Research and development$26.71M
Total operating expenses$34.39M
Operating income-$32.18M
Interest expense$3.48M
Income before taxes-$28.12M
Income taxes$0
Net income-$28.12M
Net income attributable to common shareholders-$28.12M
EBITDA-$32.18M
Basic earnings per share-$1.74
Diluted earnings per share-$1.74

Recent news

Company coverage with links to the original publishers.

Publication times in UTC

No recent company news found.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.